

**Programme Title: Clinical Policies**

Clinical Policies aim to prevent avoidable harm to patients by only offering treatments on the NHS that are evidence-based, clinically safe and effective, as well as cost effective and a good use of resources.

**Cambridgeshire, Peterborough, Bedfordshire, Luton, Milton Keynes and Hertfordshire**

<b>Title of policy and version:</b>	<b>Ophthalmology - Dysthyroid Eye Disease (TED)</b>  Version: v1.0
<b>Commissioning position:</b>	Surgical treatment of dysthyroid eye disease is NOT NORMALLY FUNDED by the ICB  Medical management of mild disease is routinely funded
<b>Scope:</b>	<ul style="list-style-type: none"> <li>• Management of dysthyroid (thyroid) eye disease (TED)</li> <li>• Clarifies ICB vs NHS England commissioning responsibility</li> <li>• Applies to requests for surgical treatment and medical management of TED</li> </ul>
<b>Cohort:</b>	Patients with dysthyroid eye disease.  Disease severity assessed using European Group on Graves' Orbitopathy (EUGOGO) criteria.
<b>Other relevant Clinical Policy</b>	TBC

<b>Treatments routinely funded:</b>	<ul style="list-style-type: none"> <li>• Medical management of mild dysthyroid eye disease, including: <ul style="list-style-type: none"> <li>○ Optimisation of thyroid function</li> <li>○ Smoking cessation support</li> <li>○ Lubricating eye drops and other conservative measures</li> </ul> </li> <li>• Moderate and severe dysthyroid eye disease (including surgical management) is commissioned by NHS England Specialised Ophthalmology (adult)</li> <li>• Spectacle lenses, including specialist lenses, are commissioned by NHS England</li> </ul>
-------------------------------------	--

--	--

<b>Treatments not funded:</b>	The ICB will not normally fund surgical treatment for mild dysthyroid eye disease
-------------------------------	---

**Rationale:**

Dysthyroid eye disease is managed according to disease severity. NHS commissioning is focused on interventions that treat disease or restore function at the appropriate level of care; mild disease is effectively managed with medical treatment, while surgical intervention is reserved for moderate or severe disease and funded by the NHSE specialised commissioning.

**IFR Statement Clinical Exceptionality:**

Where a patient does not meet the policy criteria or the intervention is not normally funded by the NHS, an application for clinical exceptionality can be considered via the ICB's Individual Funding Request (IFR) Policy and Process

<b>Coding list:</b>			

Policy document record:	Ophthalmology - Dysthyroid Eye Disease (TED) Version: v1.0
Ratification date:	1 <sup>st</sup> April 2026
Record of significant change:	v1.0 – New harmonised policy for Central ICB area, based on predecessor ICB policies (C&P, HWE, BLMK)
Planned review date:	TBC

**Document Environmental Impact statement:**  
Neutral environmental impact. Policy to be shared and stored electronically where possible; if printed, use double-sided printing and minimal copies.